Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic value of circulating tumor DNA using target next-generation sequencing in extensive-stage small-cell lung cancer.

Lung cancer (Amsterdam, Netherlands) - 1 Apr 2023

Zhang Jiexia, Zhou Ningning, Deng Huojin, Chen Xin, Chen Qunqing, Wang Qiongyao, Sun Lei, Wen Yang, Cao Xiaolong, Luo Zhiqiang, Zhang Jian, Zhu Weiliang, Guo Linlang

Abstract excerpt

BACKGROUND: Chemotherapy remains the mainstay of treatment for small-cell lung cancer (SCLC). Liquid biopsies provide a convenient and non-invasive detection method for monitoring disease progression in patients with SCLC. METHODS: We performed next-generation sequencing of 159 plasma samples from 69 patients with extensive-stage (ES)-SCLC. Circulating tumor (ct)DNA levels were quantified in haploid genome...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to DNA Copy Number Variations

Share to High-Throughput Nucleotide Sequencing

Share to Lung Neoplasms

Share to Prognosis

Share to Small Cell Lung Carcinoma

Source

Identifiers

PMID: 36758321
DOI: 10.1016/j.lungcan.2023.01.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic value of circulating tumor DNA using target next-generation sequencing in extensive-stage small-cell lung cancer.PMID 36758321Read ↗

Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations.Semantic proximity Read ↗

Clinical utility of analyzing circulating tumor DNA in patients with non-small cell lung carcinomaSemantic proximity Read ↗

Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.Semantic proximity Read ↗

Genomic Profiling of Circulating Tumor DNA from Patients with Extensive-Stage Small Cell Lung Cancer Identifies Potentially Actionable AlterationsSemantic proximity Read ↗

Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer.Semantic proximity Read ↗

Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.Semantic proximity Read ↗

Circulating tumor DNA testing in advanced non-small cell lung cancer.Semantic proximity Read ↗

Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer.Semantic proximity Read ↗

Molecular profiling in lung cancerSemantic proximity Read ↗

The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung CancerSemantic proximity Read ↗

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.